PROGENTEC DIAGNOSTICS, INC.

Commercialization Readiness of Immune Mediator Based Blood Tests that Inform Concurrent and Future Clinical Disease Activity in Systemic Lupus Erythematosus (SLE)

PROGENTEC DIAGNOSTICS, INC. is a company in national institute of allergy and infectious diseases based in Oklahoma City, OK, founded in 2015.

Profile

PROJECT SUMMARY/ABSTRACT
Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disease characterized by immune
dysregulation, disabling symptoms and progressive organ damage. Recognition and early treatment to prevent
tissue and organ damage is challenging, as signs and symptoms of high disease activity and clinical disease
flare are captured after their occurrence. Despite clinical instruments of disease activity and improved
treatment regimens to temper chronic inflammation, SLE patients may experience an average of 1.8 disease
flares annually. Current treatment for ongoing heightened clinical disease activity and disease flares, which
must be done in reactive, rather than proactive, fashion, typically relies on rapidly acting, toxic agents such as
steroids. Earlier identification and proactive treatment of heightened clinical disease activity and imminent
disease flare might prevent significant organ damage and improve the quality of life for patients with SLE.
Our scientific premise is that alterations in SLE-associated immune pathways underlie ongoing clinical
disease activity and future disease flare. Traditional biomarkers incorporated in clinical disease activity
measures, including anti-dsDNA autoantibody and complement components, are not necessarily the earliest,
nor sufficient, biologic signals of worsening disease. Using a multi-analyte approach, we lev

The company sits in the national institute of allergy and infectious diseases segment, where it competes on its core product or service.

Oklahoma City, OK is where the company is located.

Its current recorded stage is SBIR/STTR.

Recorded headcount: 11-50 employees.

It has disclosed roughly $895K in funding.

Website: progentec.com